| MedIntelliBase® NewsTips | January 2006 |
Table of Contents Please read below for news-worthy NewsTips and other information including: -- MedIntelliBase Introduction >> --On Line, On-Time, On Demand, Up-to-Date-- -- Special 40% Discount extended through January 31 -- Cardiovascular MIB MarketTrack Updates -- Endovascular MIB MarketTrack Updates -- ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
If you are tired of outdated, canned market research reports or databases that do not offer the intelligent insights and analysis you need...then MedIntelliBase is for you. Each month our MIB NewsTips e-newsletters will provide you with a glimpse into our up-to-date, for- subscription, MedIntelliBase MarketTracks - capturing in-depth the most recent market, clinical research and technology intelligence. Our first MarketTracks - the Interventional Medicine Series - cover Cardiovascular, Endovascular, Carotid Artery & Stroke, and Neurovascular Therapeutics. Take a moment to learn even more about this exciting new way to access up-to-date information and intelligence>> Visit our webpage at www.MedIntelliBase.com... ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ |
At the request of a few of our clients we also have extended our year- end offer through February 15 to allow you ample budget review time. To introduce you to our innovative products we are offering you a 40% discount on all MedIntelliBase MarketTracks. Just visit our webpage, products.html, to learn more about each of our products, and call me to place this special order. I hope you will take advantage of our limited-time offer. |
The SPIRIT III trial - "A Clinical Evaluation of the XIENCE(TM) V Everolimus Eluting Coronary Stent System (CSS) in the Treatment of Subjects with De Novo Native Coronary Artery Lesions" - is currently enrolling patients. The study will compare the XIENCE V stent with the TAXUS Express2 stent. The primary endpoint is in-segment late lumen loss (LLL) at 240 days. |
The JUPITER II study is a European multi-center trial designed to evaluate the tacrolimus-eluting Janus Carbostent compared with the bare-metal Tecnic Carbostent. The study's primary endpoint was in- stent and peri-stent LLL at angiographic follow-up. |
AVI Biopharma's Resten-MP NeuGene antisense compound (AVI-4126) is developed specifically for systemic delivery. The drug is being evaluated in Phase Ib/II clinical trials for the treatment of restenosis. |
Circulase, a prodrug of prostaglandin E(1) within lipid microspheres, is being developed as a therapy for patients with severe PAD. The first controlled trial was initiated in May 1997 with improvements in walking distance and quality of life observed. A Phase III study is currently underway evaluating the effect of Circulase in patients undergoing peripheral revascularization. |
The ACE inhibitor known as Altace, or ramipril generically, was evaluated in a study to demonstrate that the drug can improve clinical symptoms in patients with peripheral artery disease. The study's primary endpoints were time to onset of claudication, total exercise time, and walking ability. |
The TROPIC trial is designed to evaluate the safety and efficacy of Advicor, Niacin ER plus Lovastatin, in patients with intermittent claudication (IC). Percent change in peak walk time is the study's primary endpoint. As of December 2005 this trial had not been completed. |
You can find more in-depth information about the summaries noted above and many other technologies and clinical studies we have been tracking over the years in our MedIntelliBase MarketTracks >> visit our website at www.MedIntelliBase.com We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions. |
If you have a medical technology-related question, call or email me, Vicky Hunsicker Sanko. If I don't know the answer, I'll find out. You can find other related services at our sister division's website at The Next Phase® Consultancy's Home Page.
|